Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates

Journal of the American College of Cardiology

Volumn 65, Issue 8, 2015, Pages 805-815

  Valgimigli, Marco ^a   Patialiakas, Athanasios ^b,c   Thury, Attila ^d   McFadden, Eugene ^e   Colangelo, Salvatore ^f   Campo, Gianluca ^b   Tebaldi, Matteo ^b   Ungi, Imre ^d   Tondi, Stefano ^g   Roffi, Marco ^h   Menozzi, Alberto ⁱ   De Cesare, Nicoletta ^j   Garbo, Roberto ^f   Meliga, Emanuele ^k   Testa, Luca ^l   Gabriel, Henrique Mesquita ^m   Airoldi, Flavio ⁿ   Ferlini, Marco ^o   Liistro, Francesco ^p   Dellavalle, Antonio ^q   Vranckx, Pascal ^r   Briguori, Carlo ^s   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c University Hospital of Crete Medical School   (Greece)

^d UNIVERSITY OF SZEGED   (Hungary)

^e University College Cork and INFANT Centre   (Ireland)

^f MOLINETTE HOSPITAL   (Italy)

^g Azienda Unità Sanitaria Locale di Modena Ospedale   (Italy)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j Policlinico S Marco   (Italy)

^k MAURIZIANO HOSPITAL   (Italy)

^l San Donato Polyclinic and Institute for Research and Care   (Italy)

^m HOSPITAL DE SANTA CRUZ   (Portugal)

ⁿ IRCCS MULTIMEDICA   (Italy)

^o FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^p IRCCS POLICLINICO SAN DONATO   (Italy)

^q OSPEDALI RIUNITI   (Italy)

^r VIRGA JESSE HOSPITAL   (Belgium)

^s Unit of Reproductive Medicine   (Italy)

more..

Author keywords

drug eluting stent(s); dualantiplatelet therapy; high bleeding risk; high thrombotic risk; zotarolimus eluting stent(s)

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT; BIOMATERIAL; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; CORONARY STENTING; DEVICE SAFETY; DRUG ELUTING CORONARY STENT; DRUG THERAPY; DUAL ANTIPLATELET THERAPY; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; THROMBOSIS; TREATMENT DURATION; ZOTAROLIMUS ELUTING STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG ELUTING STENT; HEMORRHAGE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BIOCOMPATIBLE MATERIALS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84923356619     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.11.053     Document Type: Article

References (30)

1. P.W. Serruys, M.J. Kutryk, and A.T. Ong Coronary-artery stents N Engl J Med 354 2006 483 495
2. G.W. Stone, S.G. Ellis, D.A. Cox for the TAXUS-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. M. Valgimigli, G. Campo, G. Percoco for the Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 2008 1788 1799
4. M. Valgimigli, M. Tebaldi, M. Borghesi for the PRODIGY Investigators Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY) J Am Coll Cardiol Intv 7 2014 20 28
5. M. Valgimigli, G. Campo, S. Gambetti for the MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or Bare Metal Stent in Acute Myocardial Infarction studY Investigators Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY) Int J Cardiol 165 2013 134 141
6. B. Kalesan, T. Pilgrim, and K. Heinimann Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 977 987
7. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser for the BASKET-LATE Investgators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
8. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
9. S.B. King 3rd, S.C. Smith Jr., and J.W. Hirshfeld Jr. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209
10. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) P.G. Steg, and S.K. James ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
11. S.E. Burke, R.E. Kuntz, and L.B. Schwartz Zotarolimus (ABT-578) eluting stents Adv Drug Deliv Rev 58 2006 437 446
12. J.A. Hayward, and D. Chapman Biomembrane surfaces as models for polymer design: the potential for haemocompatibility Biomaterials 5 1984 135 142
13. M. Nishinari, T. Shimohama, and T. Tojo Two-week interval optical coherence tomography: imaging evidence on neointimal coverage completion after implantation of the Endeavor zotarolimus-eluting stent Catheter Cardiovasc Interv 82 2013 E871 E878
14. S. Li, Y. Wang, and L. Gai Evaluation of neointimal coverage and apposition with various drug-eluting stents over 12 months after implantation by optical coherence tomography Int J Cardiol 162 2013 166 171
15. D.E. Kandzari, C.S. Barker, and M.B. Leon Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents J Am Coll Cardiol Intv 4 2011 1119 1128
16. M. Valgimigli, A. Patialiakas, and A. Thury Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study Am Heart J 166 2013 831 838
17. H.P. Brunner-La Rocca, C. Kaiser, M. Pfisterer BASKET Investigators Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET) Eur Heart J 28 2007 719 725
18. D.E. Cutlip, S. Windecker, R. Mehran for the Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. G.G. Stefanini, and D.R. Holmes Jr. Drug-eluting coronary-artery stents N Engl J Med 368 2013 254 265
20. T. Wada, M. Nakahama, and H. Toda Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease ISRN Cardiol 2013 2013 518968
21. M. Valgimigli, M. Borghesi, M. Tebaldi for the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 2013 909 919
22. M. Valgimigli, G. Campo, M. Monti for the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
23. F. Feres, R.A. Costa, A. Abizaid for the OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
24. B.K. Kim, M.K. Hong, D.H. Shin for the RESET Investigators A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
25. E. Camenzind, E. Boersma, W. Wijns for the PROTECT Steering Committee and Investigators Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type Eur Heart J 35 2014 1932 1948
26. C. Fan, J.S. Kim, and J.M. Lee Different vascular healing patterns with various drug-eluting stents in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: optical coherence tomographic findings Am J Cardiol 105 2010 972 976
27. C. Rogers, and E.R. Edelman Endovascular stent design dictates experimental restenosis and thrombosis Circulation 91 1995 2995 3001
28. M. Sabate, A. Cequier, and A. Iniguez Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial Lancet 380 2012 1482 1490
29. L. Raber, H. Kelbaek, M. Ostojic for the COMFORTABLE AMI Trial Investigators Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial JAMA 308 2012 777 787
30. S.G. Ellis, M.G. Vandormael, and M.J. Cowley Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group Circulation 82 1990 1193 1202